Hereditary Renal Glycosuria, Diabetes, and Responses to SGLT2 Inhibitor

被引：0
|
作者：
Ren, Qian
Gong, Siqian
Han, Xueyao
Ji, Linong
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-774-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
774-P
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Ketonuria as an Indicator of Improvement of Renal Function in Patients with Type 2 Diabetes Receiving SGLT2 Inhibitor Treatment
    Kim, Hyun Ah
    Jang, Han Na
    Kong, Sung Hye
    Lee, Young
    Choi, Sung Hee
    Cho, Young Min
    Jang, Hak Chul
    Oh, Tae Jung
    ENDOCRINOLOGY AND METABOLISM, 2024, 39 (04) : 653 - 658
  • [32] Targeting Renal Glucose Reabsorption for the Treatment of Type 2 Diabetes Mellitus Using the SGLT2 Inhibitor Dapagliflozin
    Jabbour, Serge A.
    Whaley, Jean M.
    Tirmenstein, Mark
    Poucher, Simon M.
    Reilly, Timothy P.
    Boulton, David W.
    Saye, JoAnne
    List, James F.
    Parikh, Shamik
    POSTGRADUATE MEDICINE, 2012, 124 (04) : 62 - 73
  • [33] Role of Glycosuria in SGLT2 Inhibitor-Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE Trial
    Ferrannini, Ele
    Solini, Anna
    Baldi, Simona
    Scozzaro, Tiziana
    Polidori, David
    Natali, Andrea
    Hansen, Michael K.
    DIABETES, 2024, 73 (02) : 250 - 259
  • [34] RENAL EFFECTS AND NEPHROPROTECTION INDUCED BY THE SGLT2 INHIBITOR EMPAGLIFLOZIN IN PATIENTS WITH DIABETES MELLITUS: A LITERATURE REVIEW
    Morales-Buenrostro, Luis E.
    Citlali Juarez-Comboni, Sonia
    Aldrete Velasco, Jorge
    Rodriguez Alcocer, Alma Nelly
    REVISTA DE NEFROLOGIA DIALISIS Y TRASPLANTE, 2017, 37 (01): : 48 - 61
  • [35] Considerations for SGLT2 inhibitor use in post-transplantation diabetes
    Manfred Hecking
    Trond Jenssen
    Nature Reviews Nephrology, 2019, 15 : 525 - 526
  • [36] The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy
    Hu, Hongtu
    Li, Weiwei
    Hao, Yiqun
    Peng, Zhuan
    Zou, Zhengping
    Wei, Jiali
    Zhou, Ying
    Liang, Wei
    Cao, Yun
    CELL REPORTS MEDICINE, 2024, 5 (08)
  • [37] Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus
    Mikhail, Nasser
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (10) : 1381 - 1387
  • [38] SGLT2 Inhibitor-Induced Ketoacidosis in a Patient Without Diabetes
    Hayes, Annabelle G.
    Raven, Lisa M.
    Viardot, Alexander
    Kotlyar, Eugene
    Greenfield, Jerry R.
    DIABETES CARE, 2024, 47 (01) : e4 - e5
  • [39] Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?
    Nomiyama, Takashi
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2020, 27 (11) : 1139 - 1140
  • [40] SGLT2 inhibitor dapagliflozin lowers risk of heart failure in diabetes
    Overbeck P.
    MMW - Fortschritte der Medizin, 2018, 160 (20) : 18 - 19
12345